-
1von Batra, Rahul, Olivieri, Luis Gonzalez, Rubin, Delfin, Vallari, Ana, Pearce, Sandra, Olivo, Ana, Prostko, John, Nebbia, Gaia, Douthwaite, Sam, Rodgers, Mary, Cloherty, Gavin“… The aim of this study was to compare the performance of the Abbott Panbio(TM) COVID-19 IgG/IgM Rapid Test Device against the Abbott Architect(TM) SARS CoV-2 IgG Assay for the detection of the COVID-19 IgG antibody. …”
Veröffentlicht 2020
Volltext
Volltext
Volltext
Online Artikel Text -
2von Anderson, Mark, Holzmayer, Vera, Vallari, Ana, Taylor, Russell, Moy, James, Cloherty, Gavin“… Fingerstick plasma collected in Microtainer tubes (n = 109) showed 100% concordant results (R(2)=0.997) with matched patient venous plasma on the ARCHITECT™ SARS-CoV-2 IgG assay. High concordance of assay results (92.9% positive, 100% negative) was also observed for the PANBIO™ SARS-CoV-2 IgG assay compared to the ARCHITECT™ SARS-CoV-2 IgG assay run with matched venous plasma (n = 61). …”
Veröffentlicht 2021
Volltext
Volltext
Volltext
Online Artikel Text -
3Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohortvon Rodgers, Mary A., Holzmayer, Vera, Vallari, Ana, Olivo, Ana, Forberg, Kenn, Fuhrman, Jill, Coller, Kelly E., Awazi, Bih, Kenmegne Sidje, Jules Bertrand, Frankel, Matthew B., Berg, Michael G., Mbanya, Dora, Ndembi, Nicaise, Cloherty, Gavin A.“… All specimens were screened for HCV using the Abbott RealTime HCV viral load assay and positive specimens with remaining volume were also screened for HPgV‐2 antibodies on the Abbott ARCHITECT instrument, followed by molecular characterization. …”
Veröffentlicht 2018
Volltext
Volltext
Volltext
Online Artikel Text -
4von Pilcher, Christopher D., Louie, Brian, Facente, Shelley, Keating, Sheila, Hackett, John, Vallari, Ana, Hall, Chris, Dowling, Teri, Busch, Michael P., Klausner, Jeffrey D., Hecht, Frederick M., Liska, Sally, Pandori, Mark W.“… Newer 4(th)-generation, antigen-antibody combo rapid immunoassay (ARCHITECT) detected HIV in 87 percent of all the acute cases that had been missed by one of the previous screening assays. …”
Veröffentlicht 2013
Volltext
Volltext
Volltext
Online Artikel Text -
5von Peluso, Michael J., Takahashi, Saki, Hakim, Jill, Kelly, J. Daniel, Torres, Leonel, Iyer, Nikita S., Turcios, Keirstinne, Janson, Owen, Munter, Sadie E., Thanh, Cassandra, Nixon, Christopher C., Hoh, Rebecca, Tai, Viva, Fehrman, Emily A., Hernandez, Yanel, Spinelli, Matthew A., Gandhi, Monica, Palafox, Mary-Ann, Vallari, Ana, Rodgers, Mary A., Prostko, John, Hackett, John, Trinh, Lan, Wrin, Terri, Petroplolous, Christos J., Chiu, Charles Y., Norris, Philip J., DiGermanio, Clara, Stone, Mars, Busch, Michael P., Elledge, Susanna K., Zhou, Xin X., Wells, James A., Shu, Albert, Kurtz, Theodore W., Pak, John E., Wu, Wesley, Burbelo, Peter D., Cohen, Jeffrey I., Rutishauser, Rachel L., Martin, Jeffrey N., Deeks, Steven G., Henrich, Timothy J., Rodriguez-Barraquer, Isabel, Greenhouse, Bryan“… Variations in sensitivity and durability were particularly dramatic for individuals with mild infection, who had consistently lower antibody titers and represent the majority of the infected population, with sensitivities often differing substantially from reported test characteristics (e.g., amongst commercial assays, sensitivity at 6 months ranged from 33% for ARCHITECT IgG to 98% for VITROS Total Ig). Thus, the ability to detect previous infection by SARS-CoV-2 is highly dependent on the severity of the initial infection, timing relative to infection, and the assay used. …”
Veröffentlicht 2021
Volltext
Volltext
Volltext
Online Artikel Text